When was Enzene founded?

Enzene was founded in 2015 and raised its 1st funding round 8 years after it was founded.

Where is Enzene located?

Enzene is headquartered in Pune, India. It is registered at ALKEM HOUSE, SENAPATI BAPAT MARG LOWER PARELNA-MUMBAI-Maharashtra-400013-India.

Which legal entities is Enzene associated with?

Enzene is associated with Alkem Laboratories Limited and 3 others.

How many employees does Enzene have?

As of Apr 30, 2026, the latest employee count at Enzene is 985.

Is Enzene a funded company?

Enzene is a funded company, having raised a total of $***** in its 1st and only funding round, a Series C round on Jan 30, 2023.

When was the latest funding round of Enzene?

Enzene's latest funding was a $***** Series C round on Jan 30, 2023, with participation from 2 investors. Its primary sector is Biopharma Outsourcing. In India, the Biopharma Outsourcing sector has seen $270M in funding in 2026 to date.

What is the annual revenue of Enzene?

Annual revenue of Enzene is ₹385Cr as on Mar 31, 2025.

Where does Enzene rank among its competitors?

Enzene ranks 1st amongst 65 active competitors, of which 8 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Enzene, which secured $50M in Jan, 2023.

Who are the top competitors of Enzene?

Enzene's top competitors include Shaanxi Micot Technology, PolyPeptide and Hybio Pharmaceutical. Among them, Enzene secured the most recent funding round in January, 2023.

Enzene - 2026 Company Profile, Team, Funding, Competitors & Financials

Enzene is a series C company based in Pune (India), founded in 2015 by Chandrashekaran Siddamadappa and Kannasandra Pushpalatha. It operates as a Company specializing in development of Biosimilars. Enzene has raised $50M in funding. The company has 65 active competitors, including 8 funded and 9 that have exited. Its top competitors include companies like Shaanxi Micot Technology, PolyPeptide and Hybio Pharmaceutical.

Company Details

Enzene Biosciences Ltd., a subsidiary of Alkem Laboratories Limited, is uniquely poised to lead the new wave of global biosimilars development. Enzene has established several technology platforms in the areas of molecular biology, protein expression, fermentation technology (microbial, insect and mammalian cells), bio-analytics, immunology and peptide synthesis. The areas of expertise are: Proprietary expression vectors, Upstream Process Development for microbial, insect and mammalian cells, Downstream Process Development. Development of analytical tools to characterize peptides, proteins and mAbs, Cell Based Bioassay Development, Peptide Synthesis: Solution and Solid State

Website: www.enzene.com/
Social
Email ID: *****@enzene.com
Phone Number: +91 **********
Part Of
Registered Address: ALKEM HOUSE, SENAPATI BAPAT MARG LOWER PARELNA-MUMBAI-Maharashtra-400013-India

Key Metrics

Founded Year

2015

Location

Pune, India

Stage

Series C

Total Funding

$50M in 1 round

Latest Funding Round

Series C, Jan 30, 2023, $*****

Investors

F-Prime Capital & 2 more

Ranked

1^st among 65 active competitors

Annual Revenue

₹385Cr as on Mar 31, 2025

Employee Count

985 as on Apr 30, 2026

Similar Companies

Shaanxi Micot Technology & 72 more

View Enzene's full profile

Enzene is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Alkem Laboratories Limited CIN: L00305MH1973PLC174201 , India, Active	Aug 08, 1973	$1.59B (As on Mar 31, 2025)	19286 (As on Apr 30, 2025)
ENZENE BIOSCIENCES LIMITED CIN: U24232PN2006PLC165610 , India, Active	Aug 28, 2006	$45.6M (As on Mar 31, 2025)	685 (As on Aug 01, 2025)
ALKEM LABORATORIES LIMITED CIN: L00305MH1973PLC174201 , Vanuatu, Active	Aug 07, 1973	$1.57B (As on Mar 31, 2024)	17669 (As on Sep 30, 2023)	-
ENZENE INC. CIN: 6823271 , United States, Active	May 26, 2022	-	10 (As on Dec 31, 2024)	-

Enzene has raised a total funding of $50M over 1 round. Its latest funding round was a Series C round on Jan 30, 2023 for $*****. 2 investors participated in its latest round. Enzene has 3 institutional investors.

Here is the list of recent funding rounds of Enzene:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 30, 2023	8210363	Series C	3763871	8008385	1459525	4850541

Access funding benchmarks and valuations. Sign up today!

View details of Enzene's funding rounds and investors

The founders of Enzene are Chandrashekaran Siddamadappa and Kannasandra Pushpalatha. Himanshu Gadgil is the CEO of Enzene.

Here are the details of Enzene's key team members:

Chandrashekaran Siddamadappa: Former Co-Founder of Enzene.
Kannasandra Pushpalatha: Co-Founder of Enzene.
Himanshu Gadgil: CEO of Enzene.

Enzene's Board of Directors

Enzene's board has 3 active members. Sudha Ravi, Sandeep Singh and Vikas Gupta are part of team.

Here is the list of Enzene's board of directors:

Name	Type	Representing	Status	Duration
Sudha Ravi	Team	-	Current	4y 1m
Sandeep Singh	Team	-	Current	13y 9m
Vikas Gupta	Team	-	Current	0y 8m

View details of Enzene's Founder profiles and Board Members

Enzene's employee count trend

Enzene has 985 employees as of Apr 26. Here is Enzene's employee count trend over the years:

Uncover Enzene's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Enzene include Shaanxi Micot Technology, PolyPeptide and Hybio Pharmaceutical. Here is the list of Top 10 competitors of Enzene, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Enzene 2015, Pune (India), Series C	Company specializing in development of Biosimilars	$50M	F-Prime Capital, Eight Roads Ventures & 1 others	55/100
2nd	Shaanxi Micot Technology 2007, China, Series B	Provider of drug research and development services focused on cardiovascular and metabolic diseases	$72.2M	NLVC, Tasly & 2 others	45/100
3rd	PolyPeptide 1952, Baar (Switzerland), Public	CMO manufacturing proprietary,GMP grade and non-GMP-grade peptides	-	-	45/100
4th	Hybio Pharmaceutical 1998, Shenzhen (China), Public	Developer and manufacturer of polypeptide drugs and APis	$15M	Shenzhen Capital Group, SAIF Partners & 1 others	43/100
5th	AmbioPharm 2006, North Augusta (United States), Series B	Peptide manufacturing and development services, setting a new standard worldwide	$24M	The Carlyle Group, MVM	42/100
6th	Custom Peptide Synthesis 2011, Mumbai (India), Unfunded	Manufacturer of peptides and other finished formulations, & APIs	-	-	40/100
7th	Proteos Biotech 2010, Madrid (Spain), Unfunded	Manufacturer of recombinant enzymes and provides CMO services	-	-	38/100
8th	Rameda 1994, Giza (Egypt), Public	Developer and manufacturer of generic pharmaceuticals, nutraceuticals, food supplements and veterinary products	-	Public Investment Fund, Compass Capital	37/100
9th	USV Peptides 2011, Mumbai (India), Unfunded	CDMO offering custom peptide, GMP peptide and cosmetic peptide synthesis services	-	-	34/100
10th	JPT Peptide 2004, Berlin (Germany), Acquired	Peptide based CRO offering proteomics, biomarker and drug discovery services	-	-	32/100